481 related articles for article (PubMed ID: 25959255)
1. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Ohashi T; Yamamoto T
Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
[TBL] [Abstract][Full Text] [Related]
2. Antifibrogenic effects of C-C chemokine receptor type 2 antagonist in a bleomycin-induced scleroderma model.
Ishikawa M; Yamamoto T
Exp Dermatol; 2021 Jan; 30(1):179-184. PubMed ID: 32096250
[TBL] [Abstract][Full Text] [Related]
3. UVA irradiation following treatment with topical 8-methoxypsoralen improves bleomycin-induced scleroderma in a mouse model, by reducing the collagen content and collagen gene expression levels in the skin.
Hayashi S; Ikeda M; Kitamura Y; Hamasaki Y; Hatamochi A
J Dermatol Sci; 2012 Jul; 67(1):20-5. PubMed ID: 22486844
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.
Castelino FV; Seiders J; Bain G; Brooks SF; King CD; Swaney JS; Lorrain DS; Chun J; Luster AD; Tager AM
Arthritis Rheum; 2011 May; 63(5):1405-15. PubMed ID: 21305523
[TBL] [Abstract][Full Text] [Related]
5. Effects of thalidomide on Th17, Treg cells and TGF-β1/Smad3 pathway in a mouse model of systemic sclerosis.
Lu Y; Zhao C; Lei L; Tao Z; Zheng L; Wen J; Li X
Int J Rheum Dis; 2020 Mar; 23(3):406-419. PubMed ID: 31840939
[TBL] [Abstract][Full Text] [Related]
6. Th17 cells and IL-17 promote the skin and lung inflammation and fibrosis process in a bleomycin-induced murine model of systemic sclerosis.
Lei L; Zhao C; Qin F; He ZY; Wang X; Zhong XN
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):14-22. PubMed ID: 26750756
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of
Wen J; Lin X; Gao W; Qu B; Zuo Y; Liu R; Yu M
J Ocul Pharmacol Ther; 2019; 35(6):331-340. PubMed ID: 31343394
[No Abstract] [Full Text] [Related]
8. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
Zhao J; Wei J; Weathington N; Jacko AM; Huang H; Tsung A; Zhao Y
Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
[TBL] [Abstract][Full Text] [Related]
9. 2-Methoxyestradiol inhibits bleomycin-induced systemic sclerosis through suppression of fibroblast activation.
Zhu L; Song Y; Li M
J Dermatol Sci; 2015 Jan; 77(1):63-70. PubMed ID: 25465161
[TBL] [Abstract][Full Text] [Related]
10. Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis.
Lei L; He ZY; Zhao C; Sun XJ; Zhong XN
Int J Rheum Dis; 2016 Apr; 19(4):392-404. PubMed ID: 25545680
[TBL] [Abstract][Full Text] [Related]
11. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of skin sclerosis by 15deoxy delta12,14-prostaglandin J2 and retrovirally transfected prostaglandin D synthase in a mouse model of bleomycin-induced scleroderma.
Kohno S; Endo H; Hashimoto A; Hayashi I; Murakami Y; Kitasato H; Kojima F; Kawai S; Kondo H
Biomed Pharmacother; 2006 Jan; 60(1):18-25. PubMed ID: 16337105
[TBL] [Abstract][Full Text] [Related]
13. Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions.
Schieren G; Gambichler T; Skrygan M; Burkert B; Altmeyer P; Rump LC; Kreuter A
Am J Kidney Dis; 2010 Jun; 55(6):1040-9. PubMed ID: 20430497
[TBL] [Abstract][Full Text] [Related]
14. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
[TBL] [Abstract][Full Text] [Related]
15. EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts.
Li YJ; Azuma A; Usuki J; Abe S; Matsuda K; Sunazuka T; Shimizu T; Hirata Y; Inagaki H; Kawada T; Takahashi S; Kudoh S; Omura S
Respir Res; 2006 Jan; 7(1):16. PubMed ID: 16438734
[TBL] [Abstract][Full Text] [Related]
16. Animal model of sclerotic skin. II. Bleomycin induced scleroderma in genetically mast cell deficient WBB6F1-W/W(V) mice.
Yamamoto T; Takahashi Y; Takagawa S; Katayama I; Nishioka K
J Rheumatol; 1999 Dec; 26(12):2628-34. PubMed ID: 10606374
[TBL] [Abstract][Full Text] [Related]
17. Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(L-lactic acid) microspheres.
Shibusawa Y; Negishi I; Tabata Y; Ishikawa O
Rheumatology (Oxford); 2008 Apr; 47(4):454-7. PubMed ID: 18316335
[TBL] [Abstract][Full Text] [Related]
18. CD109 overexpression ameliorates skin fibrosis in a mouse model of bleomycin-induced scleroderma.
Vorstenbosch J; Al-Ajmi H; Winocour S; Trzeciak A; Lessard L; Philip A
Arthritis Rheum; 2013 May; 65(5):1378-83. PubMed ID: 23436317
[TBL] [Abstract][Full Text] [Related]
19. A novel inhibitor of Smad-dependent transcriptional activation suppresses tissue fibrosis in mouse models of systemic sclerosis.
Hasegawa M; Matsushita Y; Horikawa M; Higashi K; Tomigahara Y; Kaneko H; Shirasaki F; Fujimoto M; Takehara K; Sato S
Arthritis Rheum; 2009 Nov; 60(11):3465-75. PubMed ID: 19877032
[TBL] [Abstract][Full Text] [Related]
20. Local injection of latency-associated peptide, a linker propeptide specific for active form of transforming growth factor-beta1, inhibits dermal sclerosis in bleomycin-induced murine scleroderma.
Nakamura-Wakatsuki T; Oyama N; Yamamoto T
Exp Dermatol; 2012 Mar; 21(3):189-94. PubMed ID: 22188586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
